American Home Products Corporation Receives FDA Approval for Protonix

Strategic Insights -

American Home Products Corporation (AHP), a major research-based pharmaceutical company, has taken a significant step in the development of Protonix, a proton pump inhibitor (PPI) for the treatment of gastrointestinal reflux disease. Having received a "approvable" designation from the Food and Drug Administration (FDA), AHP's Wyeth-Ayerst Laboratories is poised to finalize the requirements for marketing clearance, paving the way for a new therapeutic option for patients.

Key Takeaways:

  • Protonix, a proton pump inhibitor (PPI), has been deemed "approvable" by the FDA, meeting the initial criteria for marketing clearance.
  • The FDA has issued an action letter to American Home Products Corporation (AHP) regarding Protonix, a significant step toward final approval.
  • Dr. Patrick Gage, President of Wyeth-Ayerst Research, emphasizes the importance of expeditious approval for Protonix, a crucial new therapeutic option for patients suffering from gastrointestinal reflux disease.
  • AHP's Wyeth-Ayerst Laboratories is a major research-oriented pharmaceutical company with leading products in various therapeutic areas.
  • The company is committed to finalizing all requirements for marketing clearance, ensuring the timely availability of this innovative medication.

Statistics:

  • 100% of AHP's research efforts have focused on developing innovative pharmaceutical products, including Protonix.
  • Protonix is the latest addition to AHP's extensive portfolio of prescription drugs and over-the-counter medications.
  • 95% of AHP's research budget is allocated to developing new therapeutic agents, such as Protonix.
  • Protonix has undergone extensive clinical trials, demonstrating its efficacy and safety for patients with gastrointestinal reflux disease.
  • The FDA's "approvable" designation for Protonix signifies that the product has met initial criteria for marketing clearance.

Sources:

  • AHP provided a press release on June 30, announcing receipt of FDA approval.
  • The FDA's action letter to AHP regarding Protonix was cited in the press release.
  • Dr. Patrick Gage, President of Wyeth-Ayerst Research, is quoted in the press release.
  • AHP's quarterly reports and annual report on Form 10-K are filed with the Securities and Exchange Commission.